CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to study the effectiveness of CT-2584 in treating patients who have metastatic prostate cancer that has not responded to previous therapy.

Key facts

Study ID

NCT00004026

Run by

CTI BioPharma

People needed

80

Starts

1998-12-01

Expected to finish

2005-01-01

Last updated by the study team

2020-10-19

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Stanley Scott Cancer Center — New Orleans, Louisiana, United States
• Johns Hopkins Oncology Center — Baltimore, Maryland, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Our Lady of Mercy Medical Center — The Bronx, New York, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.